Головная боль. Справочное руководство для врачей

. .,

. .,

. .

: :" 2000 .

"

-

, . , . ,

1. 1.1. 1.2. 2. 3. 3.1. 3.2. 3.3. 3.4. 3.5. 4. 4.1. 4.2. 4.3. 4.4. 5. 5.1. 5.1.1. 5.1.2. 5.1.3. 5.2. 6. 7. 8. 8.1. 8.2. 8.3.

,

.

9. 9.1. 9.2. 10. 10.1 10.2. 10.3. 11 11.1. 11.2. 12 . 12.1. 12.2. 13. 13.1. 13.2. 13.3. 13.4.

-

-

1. 2.

, ,

.

. .-

,

.

, .

.-

, .

.-

, .

(

)-

,

. .

,

50

. ,

,

,

.

,

, ,

,

. -

,

. ,

,

.

, , -

,

.

,

,

,

, .

. ,

. . ,

80%

. 70% 14%.

),

(16%);

, 25%

1%

( Gobel H. et al., ,

1994). , .

, . ;

, . . ,

.

1 ,

. -

,

2

3-6

,

,

, 7-13

.

.

1.

1.1. , ( Headache Classification Committee of

, the International Headache Society) 1988 , 1. 2. . 3. ( ) 4. , 5. 6. 7. 8. 9. 10. 11. , , , 12. , 13.

. . . . . . . . . . ,

,

,

,

. . . :

, ;

.

, ,

,

, -

,

.

. ,

,

, ( etai, 1994; Maihew N.. 1996).

. (

,

) (Olesen J.

) .

1.

: ; ; ; , : ; ; ; ;

; , ,

,

; ,

,

,

,

,

1.2. , (

, ,

,

),

,

(

,

,

). ,

,

.

, , . : ; ; , :

(

• •

(

,

,

,

,

);

,

); ,

, .

,

, , .

,

, . ,

. ,

(Goadsby P.J., 1997). . ,

, ,

.

,

-

,

:

. ). ,

,

).

,

, , .

-

. . ,

, ,

, .

0,5-2

)

, , ,

( ,

-

.

, , . .

,

, .

, ,

. . . . . ,

. , . (

,

),

,

,

.

, (

) .

. ,

, . -

. ,

,

, .

, , «

»

.

, ,

. ,

.

,

,

,

.

, ,

, , , .

. ,

,

, ,

,

,

,

, .

,

,

, ,

.

,

,

, (

, ),

.

2. . ,

, :

, (

,

. ),

(

). ,

, (

,

,

)

? ; ,

,

(

)

?

,

? ,

? ) ,

,

:

,

: : (

,

, )

?

:

?

?

?

, ( (

?

,

, .)?

,

)

? .

,

, (

,

,

.),

. . 5-10

.

,

20-40

,

(

(

3 )

,

)

. ,

.

, ,

,

,

-

.

,

. . . .

,

,

,

. ,

-

. ,

, ,

,

. ,

,

,

-

,

, .

,

,

. («

»

:

),

,

,

,

,

. , .

, ,

,

,

,

; ;

; . ,

. .

«

»

,

-

, . ( ?),

,

,

,

. , . ,

.

,

(

,

:

,

.

, , , ; ;

)

, , . :

,

(

,

,

,

);

; ; (

); ,

(

;

); ; ;

, ,

, , , ,

. ,

,

,

.

, , . ,

.

,

,

, ,

,

. ,

: (

)

;

, (

,

); ; ,

.

, ,

,

,

-

.

-

.

, ,

,

.

(

,

),

,

(

)-

.

, ,

,

.

, ( (

,

,

).

,

)

.

,

, ,

,

. (

, ,

), . , .

.

, (

,

), .

( ) )

, ,

(

, ,

.

,

, . , ,

,

,

,

.

(

,

)

,

( ) . . , ,

. , . ;

,

, . ,

,

,

. ,

,

.

-

(

,

,

) ,

,

, .

3. 3.1. -

, . . , ,

,

(

)

). ,

5

25%,

, ,

.

,

10-15% 1,5-2

. , 2

,

. , ( Rasmussen B.K. et al, 1992; Henry P. et al, 1992; Van Rojgen L. et al., 1995). , 40 , (Stewart W.F. et al, 1992).

, . .

,

35

.

, (

15

45 , ,

) ,

A.M.

., 1994). , 70%

,

, ( Lipton R.B. el al., 1993; Winnem J., 1992; Sakai F. et al.,1997). ,

,

,

,

( Lipton R.B. et al, 1995).

,

, ,

,

,

. .

1-4 1 9

.

,

,

,

. ,

.

3.2. .

,

,

,

( Wolff H.G., 1963). ,

, , .

, , . , , H.R.S., 1974). , (

,

),

(Saxena P.R. et al., 1991). ,

(

)

,

2 .

,

,

,

(

).

,

,

,

,

.

,

,

. . .

, .

,

,

, ,

(Ferrari M.D. et al, 1989). (5- 5- ) : 5- , HT1 E, 5-HT1F ( Hoyer D. et ai, 1994; Martin G.R. et al, 1994).

.55

1

5-

7.

: 5-

, 5-

, HT1D .

5-HT1D, 5, 55-

, (N0)

. ,

,

,

. ;

( ,

, , 5-

, ,

). ,

.

,

-1,

,

,

, ,.

.

(

,

)

. ,

, , ,

:

,

.

,

.

, (Moskowitz M.A. et ai, 1991).

.

, , ,

. -

, . .

.

,

, Olesen et al. (1990)

. . (

, ) ,

,

,

,

,

,

,

-

,

, .

,

, . . ,

,

,

,

.

,

. ,

, ,

.

3.3. (

, )

,

,

,

,

, ( ,

-

,

. ),

,

,

( -

)

,

,

.

, ,

. .

,

, , ,

,

, . ,

,

. ,

.

.

,

,

-

. ,

-

, ,

,

,

,

. ,

,

,

,

«

,

.

» ,

),

. ,

,

. -

.

50

26% - 14%,

10 - 14%,

40

,

, 500 , 10 20 50 - 2%

,

-

- 29%, 20 30 - 24%, 30 (Olesen J. et al., 1990). . . , . , , ,

8-12 .

40

. , . ,

, ,

,

( ,

, ,

,

, ,

, ,

),

,

,

,

,

,

-

(

,

,

),

(

,

,

,

,

,

,

,

),

,

,

. : (

,

,

,

).

,

, , ,

. ,

,

. ,

.

, . :

,

(

,

,

),

, ,

. . 1. 2. 2.1. 2.2. 2.3. 2.4. 2.5. 2.6. 3. 4. 5.

. . . . . . . . . . ,

: 5.1.

.

,

5.2. 6. 6.1. 6.2. 7.

. : . . ,

.

( 2/3

-

),

. ,

,

, ,

,

, .

, - 33%. 55%, 4

, .

500

, 4

27%

, 4 13%

24 ,

- 32%. , He

-

. ,

A. . B. 1) 2) 3) 4) . 1) 2) . 1)

- 40%, 4

1

5

.

,

. 4-72

(

). :

; ; ,

; . :

(

)

; . : ,

; 2)

, ,

;

3)

,

.

, 5-20

. (

)

, .

,

. , A. He . 1)

. 2

,

. ,

:

; 2)

4

,

; 3)

60

,

,

; 4)

60 .)

. 1)

: , ;

2)

, ,

;

.

3)

,

.

(

-

)

1/3

. :

( , ,

),

(

,

)

.

-

,

-

. ,

,

,

,

. .

,

( ,

).

,

-

.

,

,

(«

»

).

( (

)

,

),

,

;

10-15%

. . ,

,

,

. : ,

, 20-30

;

,

,

. ,

0,5-1,5 ,

, -6

.

. ,

,

.

,

.

.

(

,

), . . . , . ,

,

,

.

, .

, .

2

1

. .

,

. ,

,

,

,

, 2-3

15-20

.

.

,

,

,

.

,

. . («

»

)

, .

«

»

,

. . . .

,

,

-

5

,

. ( ,

,

,

.). : ) ; )

,

. .

.

, .

, . . ,

, , , .

, ,

.

, .

.

,

(

4

),

, )

(

.

: ,

; ,

,

72

, ,

.

,

). . (

) . ,

. ,

, ( )

.

3.4. , .

, , ,

. .

, . ,

,

. . . . ,

, -

.

3.5. -

, .

-

,

.

, .

«

»

,

. ,

,

.

,

. .

,

,

,

,

. . ,

)

, )

. ,

. . ,

,

,

,

. .

., 1998).

,

,

. .

,

-

,

.

. , . 5-

,

,

,

2-4

. , ,

(

,

.),

.

1000 500

4 ).

,

. .

( (0,04 ),

,

. . . (

,

: ,

,

)

. (500-1000

)

(50-100

), (

,

)

. ,

,

(

,

)-

, .

10

,

, .

-

, .

;

10-20

-

.

-

, ,

1.

2

, 0,1%-

juvantibus.

ex 15-20

. ,

1-2 1 .

, ,

.

,

-

,

,-

.

10-20

.

, 0,5 ,

:

2

1/2

,

.

:

,

,

. (

:

, .

).

,

,

. ,

: -

,

,

. (

)-

5-HT1

. :

,

,

( 0,5

.

)

50

,

6

100

,

( .

20

)

,

,

,

. 300

-

, 20

.

,

. .

65 ,

.

. 35-39). :

,

,

, ( (

),

)-

, 14 5-

. ,

/D

. . 2,5 2

.

,

.

,

1-5 15

. ,

.

.

(

) (

)

5-

(5-HT1) 52,5 ( ).

5-HT1 D

. 5

(

2,5

. , ).

, 4

.

,

,

,

.

,

,

. , .

,

. ®

.

50 ).

2 20

100

(

.

.

1

.

,

5-

-1 5HT1

7).

. 39-43).

IMIGRAN®

(5HT1) , .

5

(5

2-

,

,

, .

,

.

, .

,

,

. . 15

100

20

30

. ,

.

, ,

,

. . , . :

50 - 100

,

.

.

. ,

. . , 24

,

,

2 . - 300

, 20

(

18

.

) . (

65

) 65 65

.

. .

,

( ,

,

), ,

.

, . . . ). ,

(

2

. ,

. ,

.

,

, ,

, .

,

,

). . ,

40

,

. , .

.

, ,

. , . , ). . , ., , . ,

. ,

,

. . ,

24

,

,

.

,

24

.

, . , . ,

,

,

, . ,

,

,

. ,

,

.

,

. .

. :

,

,

,

,

,

. ,

-

.

: ,

.

: . ,

; .

,

,

,

,

,

-

. .

, . ® NARAMIG®

D,

GX CE5 .

,

.

2,5 2

. . . ,

. . (

, 18-65

.

): 2,5

5

(

(

2, 5

). ).

, 4

. , . . (

12-17

): .

18

.

(

12

): 12

,

. ,

65 65

,

. : . 2,5 (

(

2,5

(

). <15

)

.

: . ). . . , , ,

. , . .

5-HT1 .

. , . , . ,

, ,

, .

,

). 5-HT1

,

. ,

40

,

.

.

(

)

.

,

.

. ,

, ,

.

, , .

, .

, 450 . ,

. . ,

( ),

, . . . ,

, -

:

,

( ,

1 - 10% (

); 1%

).

,

,

. 5-

(5- HT1)

,

. (

).

( ,

) 5-

.

1

5-

5-HT1 D

5

,

.

5-

(5-

2, 5-

3, 5-

5-

4

7).

, ,

. .

,

,

. .

,

, ;

2-3 .

2,5 : 6,5-10,5

)

8,3

5,4

(95%

).

74%

63%

. (t l/2) 380

470 (220

;

, 170 .

. (29%).

(95% : 4,7-6,1

6 . .

)

, .

; 50%

, 30% -

. In vitro 450.

, .

"

"), . :

, 117418, : (095) 258 67 22,

., . 61 (095) 258 67 23

, ,

.

,

,

. ,

,

,

.

,

,

,

(

,

,

.). . . .

,

, . ,

,

.

,

,

,

,

,

,

,

:

,

,

,

. ,

.

( (

, ,

) 10%)

, ,

,

.

.

,

,

,

:

-

,

,

, .

. . -

, . ,

.

, . , ,

,

). .

, ,

10-20

. 80-120

2

3-4

. ( (

) - 50-100

,

.

) 40-160 ) 50-100

(

,

,

. -

,

,

,

.

,

,

,

. ,

. ,

.

:

,

,

,

.

.

, . , .

,

, .

, . . , ,

,

, . , . ,

, .

, ,

,

. ,

,

12,5-25 75-100

. ,

12,5-25

.

2-3-

3-6

,

. , ,

:

,

.

:

, ,

,

,

,

. (

15 -120

)

,

3-5

.

30

-

.

, (

. )

(

).

, ,

, ),

,

,

).

(

,

, . -

( ,

)

(

).

.

(25 :

)

.

,

,

. 50

. ,

,

.

,

,

,

,

,

,

. , ,

. ;

(10

120-240

)

(60-120

,

).

, :

. :

.

,

,

,

. . .

, , ,

( . . ,

,

.

)-

- 600-800 : , . .

.

(

,

,

)

3

, :

, (

, -

.). .

, , .

3-4 ,

,

,

50

-20-30

.

-

:

,

.

-

, .

,

.

,

. (

)

600-1800

,

,

. (

,

,

),

, . (

).

. .

1-2 :

2-4

2

. . .

, ,

375 .

2

2/3

,

, ,

. ,

,

.

. , ,

,

,

.

,

,

,

,

, ,

.

4. 4.1. (

)-

. ,

5-10% , 36%

13 340

,

(Oiesen J. et al., 1990). 42% 30-39 42,5% ( Upton R.B. et al.,1997).

,

;

,

47,1% .

, Petersen- Braun (1994), 64%

,

,

,

. , , 32%

, 13%

. 75%

. Gobel 58%

.

,

,

),

, .

4.2. , ,

,

:

,

,

( ,

,

, ,

,

,

), ,

,

. -

.

,

. , , .

,

,

. (Granella F. et

al, 1997), D. Simons (1998)

, , . ,

.

,

, , .

.

,

,

,

,

. : - 92%,

- 92%, - 70% .

- 76%, ( Simons D. G. et al, 1998). ,

,

, ., 1984).

, , (

),

.

, ( Landemark

. et

aL, 1990). . ,

,

,

.

(

)

.

,

, .

,

,

,

.

, ,

,

.

. ,

, (Daugard D. et aL, 1994). ,

, ( ,

),

,

.

. ,

.

4.3. ,

,

.

, ,

,

;

.

,

-

,

.

. (

,

,

). . . , . , ,

. (

), . . ,

,

, ;

,

-

,

, ,

, . 15

.

,

,

,

15

. ,

. ,

. . . 1. 1.1. 1.2. 2. 2.1.

. . .

2.2. 3.

. -

. ,

A.

10

.

,

, 180 30

. B. 1) 2)

.

15 7

.

. :

(

); (

,

); 3) 4) . 1) 2)

; . : (

);

-

(

). .

. (

)

(

)

,

. . (

)

, . .

: 1)

, ,

, ;

2)

, ,

;

3)

, . , ,

- 15

. . ,

10 ,

,

, .

7

,

15

,

. ,

. ,

. ,

,

.

. ,

,

,

. ).

,

.

,

. ,

.

, .

4.4. ,

, .

, ,

. ,

,

.

, ,-

,

. ; ,

, ,

.

-

. , . ,

. ( ,

).

-

.

, ,

.

-

.

,

50-100

12,5-25

,

.

,

. 75-100 25

,

200-250

,

.

-

. (

),

. 150

(

- 25

.

). 150

,

75

,

.

(

.

)-

.

. 25

,

,

.

:

.

(

)

12,5

2-3

.

. -

,

.

150-200

3

,

.

. (

,

)-

,

,

. ( 4

).

0,75-1,5

,

3-

. 0,5

2-3 (

. )-

.

,

.

15

100

.

,

.

: .

,

, ,

).

,

,

. (

)-

, .

, , .

12

4-6 ,

-

.

.

. .

, ,

-

.

,

, .

,

. ,

,

.

.

, ,

. ,

.

,

,

,

. . (

)

. ,

.

,

(

)

. ;

, -

,

,

.

5.

5.1. 5.1.1. (

,

,

)-

,

,

( 5-6

,

0,1-0,4%

). ,

, 8-10%

( Manzoni G.C. et ai,

1993). .

,

,

,

,

. (

),

. ( Kudrow L., et ai, 1993). , ,

,

.

( ,

,

,

,

)

,

,

(Ekbom ., 1970). 5.1.2. 20-40 ) ,

.

(

,

)

.

(

10

)

(

. ,

)

, ,

,

,

,

,

.

,

. ,

20-40

,

,

: ,

:

,

,

,

. ,

,

. 30-60

,

,

,

, . (

)

. ,

,

. 1-3

,

.

,

,

»

.

2-8 ,

,

.

. (90%

)

(10%

)

.

(

),

14

.

, 14

,

.

, .

,

.

,

. ,

. .

. .

,5

, , 15

. 1) 2) 3) 4) 5) 6) 7) 8) . . 1)

.

180

,

. :

; ; ; ; ; );

( ; .

. ,

,

:

, ,

;

2) 3)

,

;

,

. 5.1.3. .

.

,

,

,

, .

. . 7 5

10 .

60-70%

. .

, (

)

100

,

,

,

6 5

6

.

,

-

12

15

.

. .

10

,

,

. ). ,

.

, .

2 4%-

.

.

, .

,

15-20

40-60

.

7-14 .

,

, ,

,

300

,

900

. 80

,

.

,

.

5.2. -

, .

,

50 6

15

,

,

5-30

, :

,

,

,

,

,

,

. -

50-150

.

6. , , .

,

. . . .

(

,

),

)

.

,

. .

25

. ,

,

.

,

,

, ,

,

.

,

.

. ( , ,

(

, ,

5

).

. .

), ,

, . . .

, , , ,

. ,

,

. . ,

-

.

,

. 5

.

,

.

,

. , ,

. , . ,

.

.

,

, .

,

,

,

(

), .

)

(50-75

(40-80

).

7. 15-20%

.

(

(90-95%

)

),

,

(

).

-

, . . ,

-

.

, ,

,

.

(

) . (Olesen J. et al.t 1990).

25%

. , .

,

(

,

, ,

) ,

. ,

, ,

,

, . ,

-

. , . 1.

, .

25%

,

.

,

(10-15 ,

)

,

. 120

,

. ,

.

.

, .

2.

. (

.

),

130-150

,

(

.

)

. , . . 3.

. (

15-20

.

.

);

. . . , (

).

( Strandgaard S. et al., 1986). , . , . ,

,

,

.),

, ,

,

.

,, 1998). .

, ,

. , . .

,

, , ,

.

, ,

),

, . ,

,

,

, , .

,

, . », . ,

,

(

,

,

,

,

-

, , ( .),

(

, , ,

,

.), , ,

.), ,

II (

, ,

,

-

.)

.

, (

,

,

,

1-2

,

,

,

,

,

.),

. ,

,

.

(

,

,

,

),

,

.

8.

8.1. . (

,

),

,

(

300-400

)

.

,

70-80%,

- 20-25%,

(

- 5%.

,

),

,

). .

, , .

. ,

, . , .

, ,

, ,

.

,

,

, .

,

,

,

. . -

,

.

,

. , ,

, )

( ),

10%

. , ,

. . , ,

. (

) . , ( , .

,

). , -

.

, . . .

,

,

.

, . ,

,

.

,

,

(

, ). ,

,

.

, . ( ,

,

) ,

,

,

.

( ),

.

. . ,

,

.

.

,

. ,

. , . , . ,

,

.

, . (

)

, ,

,

, ,

.

.

,

,

. ,

,

. . ,

,

. .

8.2. ., 1985),

: ,

I-III

. .

(1995) . III

, . .

,

, . ,

-

. , .

(

,

, (

) )

, . ,

,

,

.

8.3. (

)-

,

. ,

. . - 70

50

);

-

.

-

.

, ,

. .

,

,

-

», .

. -

,

,

,

,

,

.

, . ,

, .

.

, . ,

4-6

, ,

60-80

.

, -

.

3-12

.

9. 9.1. 1

100 -

. ,

.

. -

(

. -

) .

,

,

,

8

, .

,

,

,

,

. , .

, ,

,

. ,

,

, . ,

.

. ,

, . ,

(

,

)

(

)

. ,

)-«

»,

. . (

-

)

. .

9.2. 8 ,

.

,

, ,

,

, ,

.

,

,

,

, ,

,

. .

,

,

,

,

. ,

( 14

), . «

»

(

)

,

, . (

)

, ,

)

, . , ,

. .

,

,

-

,

,

. , (Olesen J. et at., 1990). ,

, ,

. ,

. ,

,

,

,

, . .

, .

-

,

,

)

,

,-

.

,

, .

,

.

,

, , ,

. ,

. ,

. . , 150

(

25-50 ).

10 . 10.1 , ,

.

,

,

. , .

,

, -

,

,

,

( ),

,

.

,

,

, .

-

, . . .

(

)

. (

,

,

), . ,

,

. .

. -

. ,

,

. .

,

,

. .

200

.

.

, .

,

, .

, .

.

60-80

10.2. ,

,

,

,

. ,

,

1-2% .

et aL, 1990).

(Olesen J. .

30%

. . , (

,

,

.)

(

)

. . , .

, ,

, ,

,

.

,

, .

,

,

. ,

, ,

,

, (

). -

. ,

,

, (

,

.

,

)

. .

,

, .

10.3. -

:

,

.

,

,

,

, .

,

. , ,

,

. , )

(

)

-

(

,

. . ,

,

, , -

.

,

, . , .

,

,

,

( ,

) .

. , -

).

,

. .

11 11.1. (

)

40-60 .

,

,

, .

. ,

,

,

, (1993)

. ,

.

,

,

-

.

.

; ,

. : 1)

,

,

2)

,

(

) ;

, . .

; 3)

; 4)

,

. (Bogduk N., 1984).

,

. ,

,

.

: ,

, -

.

. . ,

.

84%

,

, 42% ( Pfaffenrath V., 1989). ( Merskey . et al., 1994), ,

, 14% , ,

. .

, .

.

, -

,

, .

, ,

,

, . :

,

, (

).

. . . , ,

.

11.2. , .

., 1993). ,

, :

. )

( .

,

.),

4,

.

12 .

12.1. ( 15-45 .

,

, ,

3-5

10-15% .

,

)

, .

,

. ,

,

,

. . ,

) .

,

-

,

. (

,

,

,

).

,

.

,

,

, «

»

.

. (

-

)

,

;

,

Classification Committee of the International Headache Society, 1988).

(Headache :

,

40

)

(

.

(

. .

)

. ,

(

,

)

. .

,

, ,

, ,

,

(

,

), ,

,

,

,

.

12.2. (

,

),

, ,

,

,

),

, ,

,

.

,

,

0,5%

,

.

, ( .

. )

. ,

,

,

).

13. 90%

(

. )

40

;

60-70%

.

13.1. , (

,

,

). ,

. (0,5-1%)

. . , , ,

. (

,

, ,

)

.

, , .

.

,

-

,

, .

13.2. (

1-2

(

)

«

»)

.

,

,

,

. (

).

,

. , . 44%,

8500 - 36%,

- 20% 5%) International Headache Society, 1988).

-

(Loeser J.D., 1990). ( Headache Classification Committee of the ,

,

.

(

,

,

)

,

.

.

,

. ,

,

. ,

,

. ,

. ,

(3-5%) .

, .

.

.

. . ,

. ,

,

. ( ,

, ,

, .

.), .

. . (Headache Classification Committee of the International Headache Society, 1988) A. , 2 . . : 1) ; 2) , , 3) ; 4) , , , 5) . B. . . . . , .

; ,

;

13.3. . -

, . ,

, ( 2/3

,

.

, .

)-

100

,

, - 600

(

600 1200-1800

,

100 200 3

).

,

,

,

. ,

. ),

(

,

),

. .

. (

)-

, .

- 300-400 1000

- 100

2

,

.

.

,

. (2-6

(15-30

)

). . ,

,

.

13.4. ,

: 1) ,

; 2)

.

,

,

1. , (Headache Classification Committee of the International Headache Society, 1988) 1. 1.1. . 1.2. : 1.2.1. . 1.2.2. . 1.2.3. . 1.2.4. . 1.2.5. . 1.2.6. . 1.3. . 1.4. . 1.5. , : 1.5.1. 1.5.2. 1.6. 1.6.1. 1.6.2. 1.7. 2. 2.1. 2.1.1. 2.1.2. 2.2. 2.2.1. 2.2.2. 2.3. 3. 3.1. 3.1.1. 3.1.2. 3.1.3. 3.1.3.1. 3.1.3.2. 3.2. 3.3. 4. 4.1. 4.2. 4.3. 4.3.1. 4.3.2. 4.4. 4.5. 4.6.

. . : . . ,

. : . . : . . .

(

) : . . : . . . ,

.

, . . : . . . . ,

:

4.6.1. 4.6.2. 4.6.3. 5. 5.1. 5.1.1. 5.1.2. 5.2. 5.2.1. 5.2.2. 6. 6.1.

. . . : (

)

. . :

(

)

. .

: 6.1.1. 6.1.2. 6.2. 6.2.1. 6.2.2. 6.2.3. 6.3. 6.4. 6.4.1. 6.4.2. 6.5. 6.5.1. 6.5.2. 6.5.3. 6.6. 6.6.1. 6.6.2. 6.6.3. 6.7. 6.8. 6.8.1. 6.8.2. 6.8.3. 6.8.4. 6.9. 7. 7.1. 7.1.1. 7.1.2. 7.2. 7.2.1. 7.2.2. 7.3. 7.4.

. . : . . . . : . . : . . . : . (

). . . : . . . . . : . . . . .

. 7.5. 7.5.1. 7.5.2. 7.6. 7.7. 8. 8.1.

: . ,

. . .

: 8.1.1. 8.1.2. 8.1.3.

. . .

8.1.4. 8.1.5. 8.2.

. . :

8.2.1. 8.2.2. 8.2.3. 8.3. 8.3.1. 8.3.2. 8.4. 8.4.1. 8.4.2. 8.4.3. 8.4.4. 8.5.

. . . : . . : . . . . :

8.5.1. 8.5.2. 9. 9.1. 9.1.1. 9.1.2. 9.2. 9.2.1. 9.2.2. 9.3. 10. 10.1. 10.1.1. 10.1.2. 10.1.3. 10.2. 10.3. 10.4. 10.5. 10.6. 11. , ,

. . : . . : . (

. : . . . . . . . . , ,

11.1. 11.2. 11.2.1. 11.2.2. 11.3. 11.3.1. 11.3.2. 11.3.3. 11.4. 11.5. 11.5.1. 11.5.2. 11.6. 11.7. 12. 12.1. 12.1.1. .

).

,

,

, . : . . : . .

. . . . , .

.

, (

)

: ,

12.1.2. 12.1.2.1. 12.1.3. 12.1.3.1. 12.1.4. 12.1.4.1. 12.1.4.2. 12.1.5. 12.1.6. 12.1.7. 12.2. 12.2.1. 12.2.2. 12.2.2.1. 12.2.2.2. 12.3. 12.3.1. 12.3.2. 12.4. 12.5. 12.6. 12.7. 12.7.1. 12.7.2. 12.8. 13.

: (

).

: . : . . . . .

. . : . . . . . ,

:

. . .

2. .

.-

..-

,

.. .

.

.

,

-

.._

.,..

..-

,

, -

,

..-

, .

, , I. +

Novartis Pharma (

)1 Zeneca LTD . . . 2,5; 5 Glaxo Wellcome Operations . . . 2,5

+

Four Ventures Enterprises . . 100

Glaxo

.6 GlaxoWellcome Operations Ltd GlaxoWellcome S.p.A.

. . . 50 20 0,1 +

.

Sandoz Pharma LTD ,

. +

+

Mag.DRT.Strallhof ER GMBH

2. +

.

+

.

« »

Biofa, Bayer

.

.

UPSA Laboratoires, A Division Of BristolMyers Squibb Natur Produkt

. .

. .

.

.

. 300 /500 . 200 /320

.

Bayer AG Laboratories RocheNicholas SA Ratiopharm GMBH & Co

.

. .

.

.

.

. .

+

.

Pliva S A Lek

-300

Heinrich Mack Nachf. Leiras

-300

Leiras

. . .

Boehringer Ingelheim Pharma KG, A Division

+

of Boehringer Ingelheim International GMBH Natur Produkt .

+ Janssen Pharmaceutica +

. Sagmel INC ICN-

.

, ,

0,25 0,05 . -

,

Perrigo Company, USA Upteka INC

. . . Pennex Labs +

. .

Natur Produkt Minerva Pharmaceutical SA

. ICNICN-

.

, , ,

, . 250

Slovakofarma SA Darou Raksh Pharmaceutical Company Arzneimittelwerk Zdravle Boehringer Ingelheim International GMBH ICN, ICN, , , ( ), , , ,

. . . . .

,

, , , , ,

, ,

, ,

-

,

, ,

, , , , , ,

.

. . .

Bristol-Myers Squibb

. .

125

Mag.DR.Strallhofer Arzneimittelwerk GMBH Teva Pharmaceutical Industries LTD

. 500

M.J.Pharmaceuticals LTD BDI Pharmaceuticals

. . 500 . 150

/5

. 500

. 500

Deva Holding AS Micro Labs LTD Al-Hikma Pharmaceuticals

. 500 . 500

Wellcome Foudation LTD .

. 250

/5 . 500

120

LekD.D. Belupo

/5 500

.

1200

/5

Slovakofarma JSC

500 Beximco Pharmaceuticals LTD Perrigo Company, USA Upteka INC

. 500 . 80

. 325; 500 Nycomed Dak AS

. 24 . 125; 500

. 500 . 125; 500

. 500 . 120

Smithkline Beecham Consumer Healthcare Smithkline Beecham Consumer Healthcare

/5 . 500 . 500

Smithkline Beecham Consumer Healthcare Smithkline Beecham Consumer Healthcare

. 500 . 300

150

ISI Pharmaceuticals INC Amoun Pharmaceutical Industries Co, APIC

/5 . 0,5 . 500

ICN Sanofi-Winthrop

0,5 . 0,5 Hemofarm D.D. . 500

120

/5 . 80;

Laboratories UPSA

150; 300; 600 Laboratoires UPSA, A Division of Bristol-Myers Squibb UPSA Laboratoires, A Division of Bristol Myers Squibb Stsds Arzneimittel AG

. 500

.

.

+ .

. . .

5 Ludwig Merckle GMBH, Merckle GMBH Merckle GMBH

.

. 500 , 125; 250; 500 200 /5 KRKA KRKA +

Nycomed Austria . . Laboratoires RocheNicholas SA Ajanta Pharma LTD

. . 3.

. Slovakofarma SA . 400 .

. 325

Apotex INC

. 250; 500 Myevska Pharmaceuticals INC, Pennex Labs Bayer AG, Biofa, Bayer, LNK International INC

. . . 325

.

.100; 325; 500 . 500 . 325; 500 « »

325

.

Natur Produkt, Sagmel INC York Pharmaceuticals INC

«

»

Hadson Corp

. . . 325 325

.

325 Sagmel INC .

. 81 Bayer AG

. . . 100; 300 Laboratoires UPSA . .

. 100 . 325; 500 .

Bayer AG

. 500 . 325

. / 81

A&Z Pharmaceutical INC

. 0,5

. 0,5 .

Ratiopharm GMBH & Co

500 .

Nycomed Christians

. . 500

. 500 ICNICNICN-

. 250; 500

, , , ICN, ICN, ,

, , , , (

),

, , , , ( ), , , , , ,

, , , , , ,

, ,

, ,

, ,

, , , ,

,

, , 000,

, , ,

, ,

0,25

.

250

, 0,5 . 500 ICNICN0,1 100

.

, ( , :

. 500 .

Slovakofarma SA

. 500 . . .

Vitec America Corporation

. 325 Vitec America Corporation . 200 . 325

OHM Laboratories INC

. 325;

Bristol-Myers Squibb

510 . 0,25; 0,5 . 500 . 500

Bayer AG Oranienburger Pharmawerk GMBH Zdravle

. 300 Novopharm LTD, ( Novopharma LTD,

.325 SpC . . . 325 -

-

75 .

. 500 -

Specifar Eli Lilly

. . 75 100

Pliva SA

)

. 100 300

.

. 300 . 300

Pliva SA MJ.Pfarmaceuticals LTD Maevska Pharmaceuticals

. 325

.

.

Lannacher Heilmittel GMBH,

50; 100 -

. 325

.

Sagmel INC ISI Pharmaceuticals, INC

+

.

. 325

.

.

Polpharma Pharmaceutical Works SA Natco Pharma LTD

.

. 350;

.

324

500 Win-Medicare .

Perrigo Company, USA Upteka INC

. Nycomed DAK

+

. 150; 500 . 100; 500 Medochemie LTD 75

. 50 /3

. Apotex INC,

. . . 25; 50

Rusan Phanna

-

. 50 / . 75

/3 Rusan Pharma

. 50 Slovakofarma SA .

. . 25; 50 M.J.Pharmaceuticals LTD

-

. 25; 50 / . 2,5% Novartis Pharma . 25; 50; 100 . 75 . . . 25; 50 Novartis Pharma AG . . . 25; 50 Novartis Pharma AG 1% Al-Hikma Pharmaceuticals

-

/ .

. 75 100 . . 100 50

Luitpold Pharma Luitpold Pharma

.

. . 50 Ct-Arzneimittel Chemishe Tempelchof GMBH

. 75 . 25; 50 . 25; 50; 100

Promed Exports PVT LTD - 25 . . . 25; 50

Merckle GMBH

.25; 50 100 . 25; 50 - / - 75 100 . 100 25 . . . . 25 50 . 50 . . 50 75

.

Berlin-Chemie AG Berlin-Chemie AG

Ber lin-Chemie AG

Berlin-Chemie AG

75 Beriin-Chemie AG .

100

. .

. 50 . 75 . . 50

-

Agio Pharmaceuticals LTD Dar Al Dava

. 100 . 50 100

75

. . Torrent Exports LTD

-

. 25;500 / . 2,5% Lannacher Heilmittel GMBH,

. 50 . 75

.

100 .

. . 100 . 75

Lupin International

. 50 . 75

Pliva D.D.

. 50 100 .

Pliva D.D.

100 .

.

Unique Pharmaceutical Laboratories

. 50 . 75 .

. 100

100 . 75

-

Alfa Schiapparelli Wassermann SPA

. 50 . 75

ICN Galenika

50 100

. 50

.

CTS Chemical Industries LTD, Hemofarm D.D., Heumann Pharma, Hexal AG, Jaka-80, Polfa, Poznanskie Pharmaceutical Works, Sofar Industria Pharmaceutical, Wave International,

-

. 25; 50 . 25; 50 100 . 75 . 25; 50 50 . 50; 100 . OOO,

-

/

Mir Pharmaceutical INC/ Pharbita B.V. Astrapin, Rotexmedica OSOO Euderma

. 25; 75

.75; 100 100

. 25; 50 .

Ratiopharm GMBH . 50; 100 Rivopharm SA

. . . 50 -

Rivopharm SA,

100 .6.2

Teva Pharmaceutical Industries LTD

100 . 50

. 75

. 75 . . 50; 100

Square Pharmaceuticals LTD

.

KRKA .50 . 50

-

/

. 100 . 75 KRKA

. 75 -50 . .

. . . . 25; 50; 100

Brown & Burk Pharmaceutical Private LTD Novopharm LTD

Mepha LTD .

.

50 , 2,5% . 2,5%

, ,

, ,

ICN-

, , ,

0,025 . 25

, , , , ,

, , ,

50 - / 100

Hemofarm D.D.

. 75

Faran Laboratories SA Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH

. 100 25 . . . 25

-

-

50 . 50 . . . 50 75 / . 75 .

Arzneimittelwerk Dresden GMBH

100

. . . 25; 50 .

Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Remedica LTD Amoun Pharmaceutical Industries Co, Apic Sanofi-Winthrop

100 . 25; 50

Panacea Biotec LTD . 25; 50 . -

-

Umedica Laboratories PVT LTD

-

. 50 / . 25

/

, 25; 50 / - 75 25 .

.

Pharmachim, Pharmachim Holding EAD Sopharma EAD Pharmachim Holding EAD, Pharmacia AD

25 . . . 100 .

100

Pharmachim Holding EAD, Pharmacia AD Laboratorio Giorgio Zoja Chimico-farmaceutica Ecosol AG

. . . 25; 50; 100 Merck Sharp & Dohme

. 250;500 WyethSPAAprila for Whitehall Apotex INC

200 . . . 200; 300; 400

KRKA Pharmaceutical Factory Kopran LTD

. . . 200 . 200; 600 100 . 200; 400 200; 400

Boots Company, Knoll AG, Knoll Pharmaceuticals LTD

/5 . /5

100

Orion Corporation . . . 200; 400 . 100 . /1,25

50

Micneil Consumer Products Company, A Division of Micneil PPC INC

/5

Sol Pharmaceuticals LTD -

/

. 2,5% Kopran LTD

. 50 . 50 Kopran LTD, .

100 Ludwig Merckle GMBH . 200; 400;

600 Olainfarm « » , Polfa, Pabianickie Pharmaceutical Works, Rugby

. 200 200 . 200; 400; 600; 800

Lannacher Heilmittel GMBH Nycomed DAK AS

. . . 400; 600 . 400; 600 . 200; 400 , 0,2 . 200

Teva Pharmaceutical Industries LTD ICNICN, ICN-

, , , ,

, , , , , , ,

, , , Sanofi-Winthrop . 200; 400 . . . 5%

Tad Pharmazeutisches Werk GMBH Dolorgiet Nycomed DAK AS

. 200

.

Amoun Pharmaceutical; Industfrries Co, Apic

. 400 . 10 /5 200 . . . 200

Berlin-Chemie AG Menarini Group Upjohn Company

. 200 . . . . 200 .

. 100

/5

Boots Healthcare International Boots Healthcare International Panacea Biotec LTD

. . . 200; 400 200

.

Remedica LTD-Minnex

200 .

Smithkline Beecham Consumer Healthcare Apotex INC,

300

. 25; 50 . 50; 100 . 25; 50 . .

1% .

Ludwig Merckle GMBH CSC Chemical Industries LTD

25 Ratiopharm GMBH & Co . 25; 50 . 25; 50 75 . 50; 100 .

-

. 25 . 25

Belupo, Berlin-Chemie AG, Chinoin, Nycomed DAK AS, Pharmachim, Pharmachim Holding EAF, Pharmacia AD, Promed Exports PVT LTD, Rugby, Sanavita Gesundcheitsmittel & Co KG, Tramedico Pharma B.V., Watson Laboratories INC, , Mir Pharmaceutical INC/ Pharbita B.V. Euderma SPA

.

75 0,025

. 25 . 100

Al-Hikma Pharmaceuticals

. 25 Panacea Biotec LTD . 25 ,

CSC Chemical Industies LTD Pharmamed LTD

75

. 25 . 3%

Polfa, Krakowskie Pharmaceutical Works

5% 75

25 . . . 25

SpC

Novopharma LTD

. 25; 50 Ethypharm 75 Bayer AG, . 5% -n 160

.

Dompe Farmaceytici SPA

. 160 . 320 . 50

Thiemann Arzneimittel GMBH LekD.D.

200 . 50 . 100

/1 150 . . . 100

100

. .

Valpharma SA

200 -

Ratiopharma GMBH & Co

. 50

Belupo Domre SPA

. . . 50; 100

. 80

30; 60 Rhone-Poulenc Rorer . 100

.

100

. 200 .

/ . 50

100 100

.

AT-50 . 100 100

Lennon LTD . . 200

.

/ . 50

100 100

. Polfa, Krakowskie Pharmaceutical Works SA, Rhone-Poulenc Rorer

. 50 .

. 100

/ .

100 . 10 . . / 100 . 50

Life Pharma .

. 100 .

. / . 50

. -

Life Pharma . Cadila Laboratories LTD

-

. 10 / . 15; 30

/ Dr.Reddy's Laboratories LTD

. 30 . . . 10 . 10 -

/

. 30

Deva Holding AS

/ F.Hoffmann-La Roche LTD F.Hoffmann-La Roche LTD manufactured by Productos Roche SA Lupin Laboratories LTD

. 30 . 10

. 30 . . . 10 . 4;

Nycomed Austria GMBH

8 Boehringer Ingelheim International GMBH

. 15 . 7,5; 15

. 250; 500 .

400

, , Laboratoires UPSA

.

Smithkline Beecham Pharmaceuticals Lek D.D. Laboratoires RocheNicholas SA Apotex INC

. 700 . 500; 750 S .1 . . . 220 125; 250; 375; 500 Syntex Pharma AG . 550 Nycomed DAK AS . . . 500 KRKA . . . 275 KRKA . . . 550 . 250; 500 . 250 -ICN

.

Lisapharma Polfa ICN-

0,25 . 250; 375; 500

.

. 25 . 125

Teva Pharmaceutical Industries LTD KRKA

. 500 /5 . 250

Syntex Pharma AG

. 250 Olainfarm 25

»

. . .5 .

Cadila Laboratories LTD Sanofi-Winthrop

. 250; 500 . 100

Helsinn Birex

100 . 100 50 /5 - 60

.

.

Dr.Reddy's Laboratories LTD Panacea Biotec LTD

. 100 . 100

Laboratorio Farmaceutico C.T.

. 100

Laboratorio Farmaceutico C.T.

.

Gedeon Richter, UPS A Laboratories, A Division of BristolMyers Squibb

.100

. 100 . 250 . 250 .

3% Apotex INC . 10; 20 .

Wockhardt LTD

. 20 . 10; 20

Genpharm INC . 10;

Novopharma LTD

20 . 20

-

. 10; 20 . 2%

/

Merckle GMBH CiplaLTD,

. 10; 20 . 20 - /

.

. 20; 40 Ipca Laboratories LTD, Jelfa SA, Jenapharm GMBH, Norton Healthcare LTD, Pharmachim, Pharmaline LTD, Polfa, ,

. 10; 20 . 10; 20 . 10; 20

10

Stada Arzneimittel AG

. 10; 20 -

Jenapharm GMBH . 10; 20 Ratiopharm GMBH & Co

. 10; 20

Teva Pharmaceutical Industries LTD ,

. 10; 20 . 10; 20 . 10; 20 -

/

. 20

HexalPharmaGMBH

/

.

Intas InternationalPharmaceuticals Laboratorio Farmaceutico C.T. Zdravle Sanofi-Winthrop Pfizer

. 20

. 20 .20 . 10; 20 . 10 /

. 20 . 10; 20

Tad Pharmazeutisches Werk GMBH

.

10;20 -

/

/

- 20

. 20

/ . 10; 20

Egis

/ . 20

KRKA

. 10; 20 . 20

Farana Laboratories SA Slaviamed Eczacibasi Biogal Pharmaceutical Works SA

. 20 . 20 . 20

.

20 . . . 20 .

.

200

. 300

.

Ranbaxy Laboratories LTI Erfa, Jugoremedia, Roussel Laboratories LTD

. 300 Roussel B.V.

.

300 Roussel Laboratories LTD .

300 .

Cilag

0,25

.250

0,15

.

, 150 , . . . 30; 50 . 20%

Weimer Pharma GMBH

. 200 .300 . 200;

Eli Lilly Lek D.D.

300 4. Lek D.D. Ljubljana . 20 . 10; 25

.

Hexal Pharma GMBH

10; 25; 50 . 10;

Remedica LTD

25 Intas InternationalPharmaceuticals Ct-Arzneimittel Chemishe Tempelchof GMBH, Indopharma, Laboratoires Ethypharma, Leciva, Polfa, Rzeszowskie Pharmaceutical Works SA, Slovakofarma SA, Weimer Pharma Nycomed Dak AS

. 25 . 25; 75 25; 50 25

. 10; 25; 50 Apotex INC, . 10; 25; 50

, .

Novopharm LTD

10; 25; 50 . 10; 25 -

/

. 10

-

/

Merck Sharp & Dohme

/

. 10

SUN Pharmaceutical Industries LTD SUN Pharmaceutical Industries LTD SUN Pharmaceutical Industries LTD SUN Pharmaceutical Industries LTD,

/

. 10; 25 + . -5 .

. . 10; 25 10; 25

SUN Pharmaceutical Industries LTD Polfa, Krakowskie Pharmaceutical Works Pfizer Corporation Apotex INC

. 10; 25; 50; 75 -

/

. 12,5

SUN Pharmaceutical Industries LTD Egis Pharmaceutical Works SA, Egis Pharmaceuticals LTD Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Novartis Pharma

/2

. 25 25 10 10 25 25 . 75 . 10; 25

-

/

25 . 25

. 25 Arzneimittelwerk Dresden GMBH /2 25

Pliva SA

-

/

. 25 SUN Pharmaceutical Industries LTD Novartis Pharma

. 25 -

/

. 25 Novartis Pharma . 10; 25; 50; 75 Hexal Pharma GMBH . 10; 25; 50; 75 .

Ludwig Merckle GMBH

25; 50; 75 CT-Arzneimittel Chemishe Tempelchof GMBH N.V.Organon Zorka Pharma

. . . 25; 50; 75 . 30 .30

F.Hoffmann-La Roche LTD . . . 150; 300 . . . 2,5 . 50

GlaxoWellcome Operations Novartis Pharma

. 20; 30

Smithkline Beecham Pharmaceuticals ,

0,025

.

25 . 25; 50 0,025 0,05

. 25 . 50 Pfizer, Pfizer Italiana SPA .50; 100

.

50; 100 . 12,5

Laboratoires Servier Orion Corporation

. 25; 50; 100 Angelini Francesco SPA 75; 150 25 . 10

Arzneimittelwerk Dresden GMBH Solvay Duphar

. . . 50; 100 : 10; 20 . 20 . 20 . 20 . 20 .

. 20

Apotex INC, Leciva JSC Lek D,D. SUN Pharmaceutical Industries LTD Eli Lilly

. 20

Egis Pharmaceuticals LTD KRKA

, 20 Orion Corporation . 20

. 10 Ranbaxy Laboratories LTD

. 20 Lannacher Heilmittel GMBH Nycomed Pharma AS

. 20 . 20

. 20 . 20 . 20; 40

Cadila Laboratories LTD H.LundbeckAS

5. 150; 300

300

KRKA

/ 5%

50

, ,

-

Sanofi-Winthrop, Torrent Pharmaceuticals LTD

. . . . 300

300

Sanofi-Winthrop

.

.

300 Sanofi-Winthrop .

. . . 300 500

Sanofi-Winthrop

. . . . . . 200 . 150;

Polfa, Rzeszowskie Pharmaceutical Works Leiras

300 Arzneimittelwerk Dresden GMBH Desitin Arzneimittel GMBH

. 300 .

. 150; 300;

600 300

/5 -

. . 300 . 300 . 200; 300

Slovakofarma SA SUN Pharmaceutical Industries LTD, Sanofi-Winthrop

.

. . 300 Marion Merrel Dow

. . . 500 Apotex INC, ,

.200 -

. 200 . 200

Gerpharm INC Pliva S A SUN Pharmaceutical Industries LTD,

. 200

Cadila Laboratories LTD, . 200 .

Nycomed DAK AS

100; 200 Rivopharma SA . 200 0,2

. 200 Teva Pharmaceutical Industries LTD Hemofarm D.D.

. 200 . 200 . 200

Sanofi-Winthrop Sanofi-Winthrop

. 400 Torrent Exports LTD . 100; 200; 400 ICN Galenika . 200 .

Novopharm LTD

200 Polpharma Pharmaceutical Works SA Remedica LTD-Minnex Novartis Pharma

. 200 . 200 . 200; 400 .

Novartis Pharma AG

200; 400 Desitin Arzneimittel GMBH . 200

.

300; 600 . 200 . .

200 200 400 400 . 200 0,25

. 0,25 1 .1 . 0,5; 2 . 0,5; 2 . 0,5; 2

Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Alkaloid Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Polfa, Tarchomin Pharmaceutical Works Remedica LTD F.Hoffmann-La Roche LTD

-

/

.1 2,5

Hoffmann-La Roche

. 5;

GlaxoWellcome Operations LTD

/

25; 10 Wellcome Foundation LTD . 25; 50; 100 ICN-

,

0,117

,

. 117

,

.

,

, 6. SUN Pharmaceuticaql Industries LD Orion Corporation

. 0,25; 0,5; 1 . 0,25; 0,5; 1

Cadila Laboratories LTD . 0,25; 0,5 0,25

Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH N.V. Upjohn Sa, Pharmacia & Upjohn NVSA Upjohn

. 0,25 0,5 . 0,5 . 0,25; 0,5; 1; 5 .

0,5; 1; 2; 3 M.J.Pharmaceuticals LTD . 0,25; 0,5; 1 . 0,25

Leciva KRKA

. 0,25; 0,5; 1 c. 3,75; 7,5; 15 c. 5; 10

Apotex INC Sanofi-Winthrop

7. . 500

Slovacopharma SA ICN-

. . . 300 8. Novartis Pharma, Sandoz Pharma, Sandoz LTD Medica, Polfa, Pharmaceutical Works, Polfarma Pharmaceutical Works SA Novartis Pharma, Pliva

. 2; 4; 6 . 10; 25

. 10; 25 9. .

Espe

20 Pierre Rolland -

/

. 4%

/

. Teva Pharmaceutical Industries LTD ,

,

, . 0,5%

, , ,

10. 1% . 10; 40

, , , , ICNOlainfarm «

, », ,

,

,' ,

ICN0,25% 0,01 .10

(

) -

0,04 . 40

( ) Apotex Inc, ,

. 10; 20; 40; 80

Natco Pharma LTD . 40; 80; 120 . 40 . . . 40

Galenika, ICI, Zeneca LTD . 160

Zeneca LTD Arab Pharmaceutical Manufacturing Co LTD Novopharm LTD, , ISIS-Chemie GMBH, ISIS Pharma GMBH, Arzneimittelwerk Dresden

. 10; 40; 80 . 10; 20; 40; 80; 120 .5 . 40 FEB .

Pharmascience Inc

10; 40 Eipico .40 Ratiofarm GMBH & Co . . . 10; 40; 80 Ludwig Merckle GMBH 80; 160 . . . 10; 40; 80 . 40 . 10; 40; 80; 160

ICN Galenica, Weimer Pharma Nycomed Dak AS

. 100

Help

. 50; 100

, Apotex Inc ,

. 25; 50; 100 . . . 50; 100 . . . 50; 100 .50; 100 . 50; 100 ,

. 50;

Kopran LTD Ecosol AG Pharmaceutical Production Ludwig Merckle GMBH, Merckle GMBH Lupin Laboratories LTD Laboratorio pharmaceutic© C.T. Lannacher Heilmittel

100 . 50; 100

GMBH,

. 25; 50 . . . 2; 5 Ratiopharm GMBH & Co 100

. . . 100 25

Ratiopharm GMBH & Co

50

Ratiopharm GMBH & Co

. . . 25 . . . 50 Teva Pharmaceutical Industries LTD Sanofi-Winthrop

.50; 100 . . . 50; 100 .50; 100

. . . 50; 100 .50; 100 -100 . . . 100 -50 . . . 50 . 25; 50;

Brown & Burk Pharmaceutical Private LTI Torrent Exports Torrent Pharmaceuticals LTD Torrent Pharmaceuticals LTD Azupharma GMBH

100 Medochemie LTD .50; 100 100

.

Remedica LTD - Minnex

100 Genpharm Inc . 50; 100 Cadila Laboratories LTD, OOO Tad Pharmaceutisches Werk GMBH Beiupo, Podravka-Belupo

.50; 100 . 50; 100 . . . 100 . 100

Galenika, ICN-Galenica Faran Laboratories SA

. 100 Leiras

. 100 . 100

Ipca Laboratories LTD

. . . 100 Alkaloida, Zeneca LTD, Lachema, ICI

. 50; 100 . 100

Nycomed Dak AS . 50; 100 . . . 25; 50; 100 . 50; 100 -100 -50

. 100 . 50

.1

Arzneimittelwerk Dresden GMBH Al-Hikma Pharmaceuticals Ci pla LTD CipIaLTD Astra, Egis SA, Eczacibasi

.

100 . 100 . 50; 100 . 50; 100 .

Slovakofarma SA Berlin-Chemie AG Novartis Pharma

.5 200 .50; 100

. 50; 100 . 50; 100 . 50 . 50;100 200 . . . 200 .50; 100 . . . 50; 100

Hexal Pharma GMBH Polpharma Pharmaceutical Works SA Ludwig Merckle GMBH, foerkle GMBH Polfa, Rzeszowskie Pharmaceutical Works Ostpharm Arzneimittel GMBH & Co KG Ostpharm Arzneimittel GMBH & Co KG Ratiopharm GMBH & Co Teva Pharmaceutical Industries Houhtamyaki Leiras, Leiras

.1 . 50; 100 Bristol-Myers Squibb, Bristol-Myes Squibb Egypt, E.R. Squibb & Sons LTD, Fako Ilaclary AS,

. 40; 80

80

. 10; 40

. 80 Bristol-Myers Squibb, A Division of Squibb Manufacturing INC , » , , , ,

ICN.40

, ,

. 10; 20; 40; 80

-

, Apotex INC, , Natco Pharma

. 40; 80; 120 . 40 . . . 40 . 160

. 10; 40; 80 . 10; 20; 40; 80; 120 . 40 . 40 . . . 10; 40; 80

Galenika, ICI Zeneca LTD Zeneca LTD Arab Pharmaceutical Manufacturing Co LTD Novopapharm LTD, , Isis Pharma Gmh Epico Ratiopharm GMBH&Co Ludwig Merckle GMBH

80; 160 . . . 10; 40; 80 ICN Galenicka, Weimer Pharma Nycomed DAK AS

. 40 . 10; 40; 80; 160 11.

AzupharmaGMBH 40; 80; 120 Sbrolek 120 -

/

.5 Nycomed Pharma AS 120; 180;

240 Themis Chemicals LTD . . . 40; 80 Ludwig Merckle GMBH -

/

.5

40; 80 .80; 120 .5 . 40; 80; 120

Alkaloid, Belupo, Chinoin, Hemopharm D.D., Norton Healthcare LTD, Mir Pharmaceutical INC/ Phaibita B.V. Ratiopharm GMBH & Co

. 40; 80; 120 , . 80; 120 , Searle, Recordati SPA, Knoll AG,

BASF Pharma -

/

. 0,25% , , 0,25%

,

.2

ICN-

, , , ,

,

ICN-

, ,

. . . 40; 80 Ethypharm . 120; 180; 240 Birlesik Alman, Enka, Ilaclary AS,LEK, Knoll AG

.5 . 40; 80 40 . . . 120; 240 240 . 40; 80

.

Knoll AG, Birlesik Alman Ilaclary AS Remedica LTD - Minnex LEK,

240 /

40; 80; 120

-

.5

-

/

. 40; .5

; 120

. 180 . 2,5

. 40;

Arzneimittelwerk Dresden GMBH Arzneimittelwerk Dresden GMBH Orion Pharmaceutica, Orion Corporation

80; 120 .

200 Mepha LTD .5 240

. . . 80; 120 . . 30

Medochemie LTD Bayer AG

. 10 . 30 .5

Torrent Exports LTD Janssen Pharmaceutica

.5 12. -

-

Laboratories Jacques Logeais

+

. -

50

13. . 5;

Apotex 1

10

/

. 10

Heumann Pharma

. 5; 10 . 10

Nycomed Christians ICN Yugoslavia

-

. 10 CTS Chemical Industries LTD Biocraft Laboratories Inc, Mir Pharmaceutical Inc Biocraft Laboratories Inc, Polfarma Pharmaceutical Works SA, Polfa, Promed Exports PVT LTD Sifar Ilaclary Sanayi AS

. 10 . 10 . 5; 10

. 10

. 10 .10

.5

-

IPCA Laboratories LTD

1 100 . 10 -

200

Alkaloid, Laboratories Delagrange, Laboratories Synthelabo Arzneimittelwerk . 10 Dresden GMBH

. 5; 10

. 10 . 10 /

Laboratories Delagrange

Rusan Pharma

. 10 . 10 . 10

.1

Cadila Laboratories LTD Gedeon Richter, Janssen Pharmaceutics

/ 10. 5 20

.5 . 20

Merck Merck

50

. 50

Merck Novopharm LTD

.5 .5

Gedeon Richter, Arab Pharmaceutical Manufacturing Co, Fabrica Socho, IPCA Laboratories LTD, Jenapharm LTD, M J. Exports Private LTD, M.J. Pharmaceuticals LTD, Polfa, Pabianickie Pharmaceutical Works, Rusan Pharma, Sanavita Gesundcheitsmittel & Co, Simpex Pharma PVT, Unichem Laboratories LTD, Wave

»

International, Bera Hafslund Nycomed Pharma AG

.

MJ.Biopharm

,

.5 . .5 -

Rivopharm SA , M

,

. 1; 5 , Schering AG

.5 ,

.

. 1. 2. 3. 4. 10). 5.

.,

.,

.,

. , . . 1998.

. .,

.:

.

, 1995. . 393-432. ., . 5. . 41-43.

. , 1984. 200 . . .:

.

.:

,1993. 400 . , «

, 1994. 286 . .

.(

-

»

6. . // . . 1985. 9. . 1281-1288. 7. . . . .: , 1987. 304 . 8. ., ., . // . 1998. 4 (10). . 7-9. 9. Bogduk N. Headache and cervical spine // Cephalalgia. 1984. N 4. P. 7-8. 10. Daugard D.t Jensen R., Olesen J. Is tension-type headache associated with neck pain or low back pain? A questionnaire-based analysis. (Abs) // Proc. of European Headache Federation (EHF). From molecules to migraine patients. Liege, 1994. 11. Ekbom Pattern of cluster headache with a note on the relation to angina pectoris and peptic ulcer//Acta Neurol Scand. 1970. V. 45. P. 225-237. 12. Evans R. W., Baskin D.S., Yatsu P.M. Prognosis of neurological disorder. Oxford: Oxford University Press, 1992. 13. Ferrari M.D., OdinkJ., Tapperelli C, Van Kempen G.M.J., Pennings EJ.M, Bruyn G. W. Serotonin metabolism in migraine // Neurology. 1989. V. 39. P. 1239-1242. 14. Goadsby P.G. Update of the anatomy and physiology of headache. (Abs.) // 2nd Congress Eur. Fed. Chapt. of IASP. Barcelona, Spain, 1997. P. 79. 15. Gobel K, Petersen-Braun M. Why patient with primary headache do not consult a doctor // Headache classification and epidemiology / Olesen J. (ed.). L.: Raven Press, 1994. V.4. P. 267-272. 16. Granella F., Sandrini G, Maccaiuso G., LantranchiS., Manzoni G.C., 17. Nappi G. Possible causative factors of tension-type headache, a case-control study (Abs.) // Cephalalgia. 1997. V. 17. P. 275. 18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain // Cephalalgia. 1988. V. 8 (Suppl 7). 96 p. 19. Henry P., Michel P., Brocket B. et al. A nationwide survey of migraine in France: prevalence and clinical features in adults// Cephalalgia. 1992 V. 12. P. 229-237. 20. Heyck H.R.S. Pathogenesis of migraine // Res Clin Studies Headache. 1974. V. 2. P. 1-28. 21. HoyerD. Clarke D.E., FozardJ.R., HartigP.R., Martin G.R., Mylecharane E.J., et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) // Pharmacol Rev. 1994. V. 46. P. 1-47. 22. International Classification of Diseases and Related Health Problems (ICD-10). Guide for headache//Cephalalgia. 1997 V. 17. (Suppl. 19). P. 14-17. 23. Kudrow L/Kudrow D.B< The role of chemoreceptor activity and oxyhemoglobin desaturation in cluster headache // Headache. 1993. V. 33. P. 483-484. 24. Landemark M., Jensen K., Olesen J. Temporal muscle blood flow in chronic tension-type headache // Arch Neurol. 1990. V. 47. P. 654-658. 25. Lipton R.B.,Stewart W.F. Migraine in the United States: A review of epidemiology and health-care use // Neurology. 1993. V. 43 (Suppl 3). P. 6-10. 26. Lipton R.B.,Stewart W.F., Von KorffM. Migraine impact and functional disability // Cephalalgia. 1995. 15 (Suppl 15). P. 4-9. 27. Lipton R.B.,Schwartz B.S.,Stewart W.F. Epidemiology of tension-type headache. (Abs.) // Cephalalgia. 1997. V. 17. P. 233. 28. LoeserJ.D. Cranial neuralgias // The management of pain / Bonica J.J. (ed.), 1990. V. 1. P. 676-686. 29. Manzoni G.C., Prusinski A. Cluster headache: introduction // The headaches / Olesen J., Tfelt-Hansen P., Welch K.M.A. (eds.),

New York: Raven Press, 1993. P. 543-545. 30. Mathew N. T. Chronic daily headache. Pain 1996. In updated review. IASP-Press, 1996. P. 143-153. 31. Martin GR, Humphrey P.P.A. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature // Neuropharmacol. 1994. V. 33. P. 261-273. 32. Merskey H.f Bogduk N. Classification of chronic pain. Seattle: IASP-Press, 1994. P. 94-95. 33. Moskowitz M.A., Buzzi M.G. Neuroeffector functions of sensory fibres; implications for headache mechanisms and drug actions // J Neurol. 1991. V. 238. P. 18-22. 34. Moskowitz M. A. Migraine: new concepts, new mechanisms, new drugs // Towards Migraine 2000 / Rose F.C. (ed.) Elsevier, 1996. P. 219-228. 35. Olesen J.f Bonica J J. Headache // The management of pain/Bonica JJ. (ed.), 1990. Vol.1. P. 687-726. 36. Olesen J.f Tomsen L.L., Iversen NK. Nitric oxyde is key molecule in migraine and other vascular headaches // Trends in Pharmacological Sciences. 1994. V. 15. P. 149-153. 37. Pfaffenrath V. Der zervikogene korfshmersz ein uber - oder unterdiagnotiziertes kopfshmerz syndrom? // Fortschr Med. 1989. V. 107. P. 189-193. 38. Rasmussen B.K., Cull R.E., Wells N.E.J., Miocevich Af.L. The economic cost of migraine// Br J Med Econ. 1992. V. 2. P. 103115. 39. Sakai F., Igarashi H. Epidemiology of migraine in Japan: a nationwide survey // Cephalalgia. 1997. V. 17. P. 15-22. 40. Saxena P.R, Den Boer M. 0. Pharmacology of antimigraine drugs // J Neurol 1991. V. 238. P. 528-535. 41. Simons D.G., Mense S. Understanding and measurement of muscle tone as related to clinical muscle pain (Review article)// Pain. 1998. V. 75. P. 1-17. 42. Stewart W.F.,Lipton R.D., Celentano D.D. et al.Prevalence of migraine headache in the United States // JAMA. 1992. V. 267. P. 64-69. 43. Strandgaard S., Olesen G., Paulson O. The cerebral circulation in hypertension// Handbook of hypertension /A. Zanchetti, R.C. Tarazi. (eds.) Amsterdam, 1986. V. 7. P. 253-279. 44. Van Rojgen L., Essing-Bot M-L., Koopmanschap MA, et al. Societal perspective on the burden of migraine in the Netherlands// PharmacoEconomics. 1995. V. 7. P. 170-179. 45. Winnem /. Prevalence of adult migraine in general practice//Cephalalgia. 1992. V. 12. P. 300-303. 46. Wolff H. G. Headache and other head pain. 2nd ed. Oxford: Oxford University Press, 1963. P. 269.

«

».

. -

«

«

017666

29

»

1998 .

10.01.2000 . " ©

".

10000

«

«

»

© 101442, .

,

.,

. (095) 978-4673/2168/3755/1058 -

23 . 978-8082 .

. . .

.